Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Core Insights - AnaptysBio, Inc. is hosting an investor call and live webcast to discuss updated data from the Phase 2b RENOIR clinical trial of rosnilimab for rheumatoid arthritis on June 3, 2025 [1] - The event will feature key management members and clinical trial investigators, highlighting the company's commitment to transparency and investor engagement [2] Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases [4] - The lead program, rosnilimab, is currently in a Phase 2b trial for rheumatoid arthritis and a Phase 2 trial for ulcerative colitis [4] - The pipeline includes ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator, both in Phase 1 trials [4] - The company has collaborations with GSK for multiple therapeutic antibodies, including a PD-1 antagonist and a TIM-3 antagonist [4] Upcoming Events - AnaptysBio's executive leadership will participate in several investor conferences following the data release, including the Jefferies Global Healthcare Conference and the Goldman Sachs 46th Annual Global Healthcare Conference [3] - Live webcasts of the data release and subsequent presentations will be available on the company's investor website, with replays accessible for at least 30 days [3]